Abstract
Primary proteinuric kidney diseases (PPKD) as a group are an important cause of end-stage kidney disease (ESKD). Many receptor tyrosine kinases, including platelet-derived growth factor receptor (PDGFR), contribute to the progression of PPKDs to ESKD. ANG-3070 is a novel and proprietary inhibitor of multiple tyrosine kinases including PDGFR. This study evaluated the effects of ANG-3070 in a passive Heymann nephritis (PHN) rat model of membranous glomerulopathy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
